Kronos Bio提供了很有希望的KB-9558临床预科数据,KB-9558是一种针对HPV驱动肿瘤的P300KAT抑制剂,有可能进行定向治疗。 Kronos Bio presented promising preclinical data on KB-9558, a p300 KAT inhibitor targeting HPV-driven tumors, with potential for targeted therapy.

Kronos Bio宣布其P300 KAT抑制剂KB-9558的临床预科数据很有希望,针对的是HPV驱动的肿瘤,包括头部、颈部、宫颈癌和厌生癌。 Kronos Bio announced promising preclinical data on its p300 KAT inhibitor, KB-9558, targeting HPV-driven tumors, including head, neck, cervical, and anogenital cancers. 该研究在EORTC-NCI-ACR专题讨论会上提出,研究显示,禁止P300KAT活动有选择地减少了HPV肿瘤E6和E7的表达方式,恢复肿瘤抑制路径p53和Rb。 Presented at the EORTC-NCI-AACR Symposium, the study revealed that inhibiting p300 KAT activity selectively reduces the expression of HPV oncogenes E6 and E7, restoring tumor suppressor pathways p53 and Rb. 目前,没有针对这些蛋白质的定向治疗方法,这凸显了KB-9558的潜力。 Currently, no targeted therapies exist for these oncogenes, highlighting KB-9558's potential.